Company Further Examining the Pursuit of the World's First Oral Liraglutide Product KELOWNA, BC / ACCESS Newswire / February 5, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce final results from Human Pilot Study #5 (GLP-1-H25-5) (the "Study"), which compared oral DehydraTECH-liraglutide ("DHT-LIR") capsules to injected Saxenda® branded liraglutide ("SAX-LIR"). "We are extremely pleased with the results of Huma ...

Core Viewpoint - Lexaria Bioscience Corp. has achieved a significant milestone by securing a total of 60 valid patents globally, enhancing its intellectual property portfolio and positioning itself for future commercial opportunities [1][9]. Patent Developments - The company has successfully obtained 6 new patents since its last update on October 9, 2025, indicating a proactive approach to intellectual property development [2]. - In Patent Family 20, Lexaria received its first patent in Australia for sublingual delivery of nicotine, complementing existing patents in the US, Canada, and Japan [3]. - The company has also secured its first European Union patent in Patent Family 21 for treating hypertension, which is significant given that Europe is the second-largest hypertension market globally [4]. - In Patent Family 24, Lexaria has strengthened its position with 2 new Australian patents and 1 new European Union patent for treating epilepsy, bringing the total to 6 US patents, 4 Australian patents, and 1 European Union patent [5]. - Additionally, in Patent Family 27, Lexaria has received 1 new US patent for treating diabetes, now holding 2 US patents in this family, which is crucial due to recent successes in the GLP-1 sector [6]. Research and Development - Lexaria's innovations are supported by a rigorous process that includes research, animal and human testing, and subsequent patent applications, allowing the company to pursue commercial relationships post-patent grants [7]. Shareholder Engagement - The company is reminding shareholders to vote in the upcoming Annual Meeting scheduled for January 27, 2026, emphasizing the importance of shareholder participation [8][10].

Financial Performance - The company reported a revenue of $2.5 billion for Q2 2023, representing a 15% year-over-year increase[1]. - The company provided guidance for Q3 2023, expecting revenue to be between $2.6 billion and $2.8 billion, indicating a potential growth of 8% to 12%[3]. - Revenue from B2B sales for the three months ended November 30, 2025, was $183,923, a decrease of $9,923 compared to the same period in 2024, reflecting a shift away from B2B clients towards pharmaceuticals[136]. - The company reported a net loss of $1,597,503 for the three months ended November 30, 2025, compared to a net loss of $2,706,628 for the same period in 2024, indicating a reduction in losses year-over-year[131]. - The company incurred a net loss of $1,595,712 for the three months ended November 30, 2025, compared to a net loss of $2,706,628 for the same period in 2024[146]. - Net cash used in operating activities was approximately $1.0 million for the three months ended November 30, 2025, a significant decrease from $2.7 million in the same prior year period[143]. Research and Development - The company completed a Phase 1b clinical study showing good safety and tolerability of DehydraTECH formulated cannabidiol and semaglutide, with clear reductions in adverse events compared to the Rybelsus® control arm[117]. - Lexaria's DehydraTECH technology improves the delivery of Active Pharmaceutical Ingredients (APIs), potentially lowering overall dosing and enhancing bioavailability across various product categories[110]. - The company anticipates ongoing clinical research programs in cardiometabolic health, particularly for diabetes and weight loss treatments[113]. - The FDA provided a Study May Proceed letter for the IND application related to DehydraTECH-CBD for hypertension, allowing the company to advance its clinical trials[124]. - The company completed a human study (GLP-1-H24-4) with over 100 participants, demonstrating good safety and tolerability of DehydraTECH formulations compared to the Rybelsus® control arm[121]. - Long-term stability testing of DehydraTECH compositions is ongoing, with positive findings meeting internal expectations for chemical and microbiological purity[123]. - The company is exploring various therapeutic indications for DehydraTECH, including diabetes and weight loss treatments, with ongoing R&D programs[120]. - Research and development expenses increased by 12%, focusing on innovative technologies for product enhancement[7]. - Research and development expenditures decreased by $1,281,880 year-over-year for the three months ended November 30, 2025, as the company neared completion of its Phase 1b Clinical Trial[137]. Intellectual Property and Acquisitions - The company has several patents pending worldwide, specifically for the use of DehydraTECH with GLP-1/GIP drugs and cannabinoids for treating diabetes and heart disease[113]. - Lexaria's patent portfolio includes granted patents related to food and beverage compositions infused with lipophilic active agents, enhancing the effectiveness of API delivery[116]. - The company plans to continue seeking beneficial acquisitions of intellectual property to expand its portfolio[114]. - A strategic acquisition of a smaller competitor was completed, expected to contribute an additional $300 million in annual revenue[6]. Market Strategy and Expansion - The company is expanding its market presence in Asia, targeting a 20% increase in sales in the region by the end of 2024[5]. - New product launches included a line of enhanced delivery systems for lipophilic active agents, projected to increase market share by 5%[4]. - A new marketing strategy was implemented, aiming to boost brand awareness and customer engagement by 30% over the next year[9]. Financial Position and Funding - The company raised $3.4 million in net proceeds from a Registered Direct offering that closed in September 2025[132]. - The company has incurred recurring losses and negative cash flows from operations, with expectations of increased expenditures related to ongoing R&D programs, particularly for GLP-1 drugs and hypertension treatments[130]. - The company expects its current cash resources to fund operations through the first quarter of fiscal year 2027, but there is substantial doubt about its ability to continue as a going concern[133]. - The company plans to fund operations through equity financing arrangements and potential collaborations or strategic partnerships[149]. - Share issuance costs of $0.6 million were charged to additional paid-in capital during the recent financing[111]. - As of November 30, 2025, the company had current assets of $5,363,129 and current liabilities of $1,456,534, resulting in net working capital of $3,906,595[141]. - Cash and cash equivalents as of November 30, 2025, were approximately $4.3 million, which is expected to be insufficient to meet financial obligations for the next twelve months[149]. Operational Efficiency - The company reported a 25% increase in gross margin, attributed to improved operational efficiencies[8]. - Other general and administrative expenses decreased by $197,558, mainly due to lower spending on advertising and promotions[140]. - Consulting fees and salaries increased by $31,272 year-over-year, primarily due to cost of living adjustments, offset by reduced consulting fees and lower stock-based compensation[138]. - Legal and professional fees rose by $149,887 during the three months ended November 30, 2025, due to higher accounting and professional fees related to financing activities[139].

Core Insights - Lexaria Bioscience Corp. has made significant advancements in oral drug delivery technology, particularly in the GLP-1 sector, utilizing its proprietary DehydraTECH™ (DHT) technology [3][11][60] - The company reported a substantial increase in the market for GLP-1 drugs, with worldwide revenues rising from $34.4 billion in 2024 to $51.9 billion in 2025, marking a 51% year-over-year growth [8] - Lexaria's DHT technology has shown promising results in reducing adverse events (AEs) associated with GLP-1 drugs, which are primarily injectable, thus presenting a significant market opportunity [12][14][58] 2025 Highlights - In 2025, Lexaria focused its resources on studying its DHT technology with the three leading GLP-1 drugs: semaglutide, tirzepatide, and liraglutide [5][6] - The company completed its first Phase 1b registrational study in Australia, achieving a gross total of $9.5 million through three equity raises [6][49] - Lexaria's DHT technology demonstrated positive results across all R&D studies conducted in 2025, including significant reductions in AEs [6][58] Market Dynamics - The GLP-1 drug market is becoming increasingly competitive, with new companies and products emerging regularly, and existing drugs expanding their indications beyond diabetes and weight loss [9] - Despite the overall market growth, the orally-delivered segment of GLP-1 drugs has seen limited revenue growth, with only 5% of total revenues from oral products in 2025 [10] Research and Development - Lexaria's studies in 2025 included Human Pilot Studies that showed DHT-processed drugs had reduced AEs compared to their injectable counterparts, with notable reductions in gastrointestinal issues [18][29] - The company plans to leverage findings from its 2025 studies to design new R&D work in 2026, focusing on improving oral GLP-1 formulations [34][36] Collaboration and Business Development - Lexaria has extended its Material Transfer Agreement (MTA) with a pharmaceutical partner to evaluate DHT technology, allowing for continued collaboration and strategic planning [41][43] - The company is actively pursuing discussions with various pharmaceutical companies for potential partnerships, not only in the GLP-1 sector but also in other therapeutic areas [46][48] Financial Overview - Lexaria raised $9.5 million in 2025, successfully capitalizing on favorable market conditions to fund its R&D activities through 2026 [49][50] - The company has sufficient funding to support its operations and marketing campaigns in 2026, despite previous stock price weaknesses [55][56] Future Outlook - Lexaria aims to develop the world's first oral version of liraglutide using DHT and is exploring additional R&D opportunities outside the GLP-1 sector [63][40] - The company is committed to advancing its DHT technology and believes it is closer to a commercial breakthrough than ever before [60][61]

Core Insights - Lexaria Bioscience Corp. has released additional data from its Phase 1b clinical study GLP-1-H24-4, which focuses on the efficacy of its DehydraTECH™ technology compared to Rybelsus® [1][2] Secondary Efficacy Parameters - At week 16, the DHT arms showed no statistically significant differences compared to the Rybelsus® control in mean fasting glucose, cholesterol, and LDL cholesterol [3] Body Composition - The DHT-semaglutide arm showed a modest reduction in fat mass of -1.08 kg and total mass of -1.40 kg, while the Rybelsus® control arm achieved greater reductions of -3.55 kg in fat mass and -5.36 kg in total mass, with a higher reduction in lean mass of -1.72 kg [4] Blood Pressure Analyses - The DHT-CBD arm achieved significant reductions in blood pressure, with a mean change of -4.6 mmHg in systolic and -4.0 mmHg in diastolic blood pressure at week 4 [5][6] Pharmacokinetic Exploratory Analyses - Plasma CBD concentrations were quantifiable through week 16 in the DHT-CBD arms, while semaglutide concentrations were not quantifiable due to assay issues, although preliminary tests indicated measurable levels [8] Health Survey Results - Participants in the DHT-semaglutide arm reported mean improvements of over 5 points in physical components and over 3 points in mental components of the SF-36 health survey, compared to modest improvements in the Rybelsus® control arm [9][10] Overall Conclusions and Next Steps - The study met its primary endpoint, demonstrating good safety and tolerability of all DHT test articles, with positive findings across various parameters compared to Rybelsus® [11] Future Plans - Lexaria plans to pursue further clinical testing with a DHT + SNAC + semaglutide composition and is in discussions with a pharmaceutical company regarding the dataset from the study [15][17][18]

Core Insights - Softbank has completed its $40 billion investment commitment to OpenAI, with a final investment of $22 billion to $22.5 billion sent last week [1] - The total investment includes a previous $10 billion syndicated and $8 billion directly invested in OpenAI [1] - The investment values OpenAI at a pre-money valuation of $260 billion [1] Funding Details - The funding will be disbursed over a 12 to 24 month period [2] - Part of the investment is intended to support OpenAI's artificial intelligence infrastructure through the Stargate joint venture with Oracle and Softbank [2]

Core Viewpoint - Air China and its subsidiary have signed an agreement with Airbus to purchase 60 A320NEO jets, valued at approximately $9.5 billion at list prices [1] Company Summary - Air China is expanding its fleet by acquiring 60 A320NEO jets from Airbus [1] - The total value of the deal is around $9.5 billion, indicating a significant investment in modernizing and expanding its aircraft capabilities [1] Industry Summary - The agreement reflects ongoing demand for new aircraft in the aviation industry, particularly for fuel-efficient models like the A320NEO [1] - This purchase may enhance Air China's competitive position in the market as airlines increasingly focus on sustainability and operational efficiency [1]

Core Insights - SoftBank Group has finalized a $40 billion investment in OpenAI, as reported by CNBC, citing sources familiar with the matter [1] Company Summary - The investment by SoftBank Group in OpenAI amounts to $40 billion, indicating a significant financial commitment to the artificial intelligence sector [1]

Core Insights - Lexaria Bioscience Corp. has successfully completed its Phase 1b, 12-week chronic study GLP-1-H24-4 in Australia, demonstrating superiority in reducing side effects compared to Novo Nordisk's Rybelsus [1][2] Study Results - The study achieved its primary endpoint, showing that all four DehydraTECH (DHT) formulations were safe and well tolerated, with lower rates of treatment-emergent adverse events (AEs) compared to Rybelsus [3] - DHT-semaglutide showed a 47.9% reduction in total AEs and a 54.9% reduction in gastrointestinal AEs compared to Rybelsus [4] - The reduction in HbA1c levels was comparable between DHT-semaglutide and Rybelsus, but bodyweight reduction was better in the Rybelsus arm at both week 12 and week 16 evaluations [5] Future Development - Lexaria plans to further develop the DHT-semaglutide formulation and is considering incorporating salcaprozate sodium (SNAC) in future studies [6] - The company is evaluating options for follow-on human clinical testing of a DehydraTECH + SNAC + semaglutide formulation against Rybelsus [6][7] Market Reaction - Following the news, Lexaria's stock (LEXX) experienced a decline of 7.42%, trading at $0.63 [8]

Core Insights - Lexaria Bioscience Corp. has successfully achieved its primary endpoint in the Phase 1b study GLP-1-H24-4, demonstrating significant efficacy in reducing unwanted side effects compared to Rybelsus® [2][13] - The company raised a total of $7.5 million through financing activities, which will support new development opportunities throughout 2026 [2][18] - The study results indicate that DehydraTECH-semaglutide reduced overall side effects by 48% and gastrointestinal side effects by 55% compared to Rybelsus® [4][6] Study Results - All four DehydraTECH (DHT) test articles were found to be safe and well-tolerated, meeting the primary endpoint objective [3][13] - The total adverse events (AEs) for DHT-semaglutide were reduced by 47.9% compared to Rybelsus®, with a statistically significant reduction in gastrointestinal AEs [6][10] - The study included 126 participants, focusing on safety and tolerability, with DHT-semaglutide showing the best performance among the tested formulations [19] Efficacy Assessments - The primary efficacy endpoint of HbA1c reduction showed comparable performance between DHT-semaglutide and Rybelsus®, with no statistically significant difference [10][11] - Bodyweight reduction was more pronounced in the Rybelsus® control arm compared to all DHT arms, raising questions about the differing results [11][12] - The study's findings suggest that even small reductions in HbA1c can improve cardiovascular outcomes in overweight or obese individuals [10] Future Directions - Lexaria plans to investigate the DHT-semaglutide formulation further, potentially incorporating salcaprozate sodium (SNAC) in future studies [14][15] - The company aims to relay the study dataset to its pharmaceutical partner under a Material Transfer Agreement, which has been extended to April 30, 2026 [16][17] - Additional non-primary endpoint results are expected to be released soon, providing further insights into the study's findings [20]